UDK: 616.992:582.282.123.4]-097
Mirchevska G.
1Institute of Microbiology and Parasitology, Faculty of Medicine Skopje, Ss Cyril and Methodius University Skopje, Republic of North Macedonia
| Mirchevska Gordana | https://orcid.org/0009-0004-3898-7143 |
Abstract
Introduction: Aspergillosis is a major threat to immunocompromised hosts, but also to immunocompetent patients.Early diagnosis remains a diagnostic challenge, and there is a need for rapid and sensitive diagnostic methods.
Aim: The aim of the study was to compare the diagnostic value of serum PCR assay with serum galactomannan antigen test, in the diagnosis of both invasive and non-invasive aspergillosis.
Material and methods:During a period of two years (2014 – 2016), sera from 125 patients divided into 4 groups (group I-immune deficiency, group II-prolonged stay in ICU, group III-chronic aspergillosis, group IV-cystic fibrosis), classified according to clinical diagnosis and EORTC/MSG criteria, were analysed at the Institute of Microbiology and Parasitology, Faculty of Medicine Skopje, with molecular (PCR) and serological methods (galactomannan.
Results:PCR in serum demonstrated the following sensitivity and specificity:53.57% and 100% in group I, 36.36% and 100% in group II, 9.09% and 100% in group III, respectively. Serum PCR was not performed in the cystic fibrosis group. The sensitivity and specificity of galactomannan in serum were 64.29% and 57.14%, 40.91% and 62.5%, and 40.91% and 62.5% in groups I, II, and III, respectively.
Conclusion: Our results indicate that both PCR and galactomannan in serum could be useful adjunct tests for the diagnosis of both invasive and non-invasive aspergillosis, so an early antifungal treatment is initiated in order to achieve a more favorable clinical outcome.
Keywords:Aspergillus; aspergillosisserum galactomannan; serum PCR.
References:
1.Bocci MG, Cascarano L, Capecchi G, Lesci A, Sabatini V, Rubino D, Stazi GV, et al. Pulmonary aspergillosis in immunocompromised critically ill patients: prevalence, risk factors, clinical features and diagnosis—a narrative review. J Fungi (Basel). 2025;11(9):617. doi:10.3390/jof11090617.
2.Mirchevska G, Kotevska V, Kaftandzieva A, Kirovski I, Stojanoski Z, Trajkovska-Dokic E1 Evaluation of BAL PCR for diagnosis of aspergillosis. Macedonian Journal of Anesthesia. 2022;6(2):10-21.
3.Zubovskaia A, Vazquez JA. Invasive aspergillosis in the intensive care unit. J Fungi (Basel). 2025;11(1):70. doi:10.3390/jof11010070..
4.Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. Eur Respir Rev 2011;20(121):156-74. doi: 10.1183/09059180.00001011.
5.Barton RC. Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Scientifica (Cairo). 2013; 2013:459405. doi: 10.1155/2013/459405.
6.Bassetti M, Azoulay E, Kullberg BJ, Ruhnke M, Shoham S, Vazquez J, Giacobbe DR, Calandra T. Bassetti M, Azoulay E, Kullberg BJ, Ruhnke M, Shoham S, Vazquez J, et al. EORTC/MSGERC definitions of invasive fungal diseases: summary of activities of the intensive care unit working group. Clin Infect Dis. 2021;72(Suppl 2):121-127. doi:10.1093/cid/ciaa1751.
7.Skladny H, Buchheidt D, Baust C, Krieg-Schneider F, Seifarth W, Leib-Mösch C, et al. Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR. J Clin Microbiol. 1999;37(12):3865-3871. doi:10.1128/jcm.37.12.3865-3871.1999.
8.PlateliaTM Aspergillus Antigen from
http:www.bio-rad.com/webroot/web/pdf/inserts/CDG/en/62784_881082_EN.pdf
9.Suarez F, Lortholary O, Buland S, Rubio MT, Ghez D, Mahé V, Quesne G, Poirée S, Buzyn A, Varet B, Berche P, Bougnoux ME. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. J Clin Microbiol. 2008;46(11):3772-7. doi: 10.1128/JCM.01086-08.
10.Hites M, Goicoechea Turcott EW, Taccone FS. The role of galactomannan testing to diagnose invasive pulmonary aspergillosis in critically ill patients.Ann Transl Med. 2016;4(18):353. doi: 10.21037/atm.2016.08.32.
11.Arvanitis M, Anagnostou T, Mylonakis E. Galactomannan and polymerase chain reaction–based screening for invasive aspergillosis among high-risk hematology patients: a diagnostic meta-analysis. Clin Infect Dis. 2015;61(8):1263-1272. doi:10.1093/cid/civ555.
12.Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(2):89-96. doi: 10.1016/S1473-3099(09)70019-2
13.Egger M, Jenks JD, Hoenigl M, Prattes J. Blood Aspergillus PCR: the good, the bad, and the ugly. J Fungi (Basel). 2020;6(1):18. doi:10.3390/jof6010018.
14.Raad I, HannaH, SumozaD, Albitar M. Polymerase chain reaction on bloodfor the diagnosis of invasive pulmonary aspergillosis in cancer patients. Cancer. 2002;94(4):1032-1036.DOI 10.1002/cncr.10349.
15.Arvanitis M. PCR in diagnosis of invasive aspergillosis: a meta-analysis of diagnostic performance. J Clin Microbiol. 2014;52(10):3731-42. doi: 10.1128/JCM.01365-14.
16.Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42(10):1417-27. doi: 10.1086/503427.
17.Leeflang MM, Debets-Ossenkopp YJ, Wang J, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Zhang M, Bossuyt PM, Vandenbroucke-Grauls CM. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2015;2015(12):CD007394. doi: 10.1002/14651858.CD007394.pub2.
18.Cruciani M., Mengoli C., Barnes R., Donnelly J.P., Loeffler J., Jones B.L., Klingspor L., Maertens J., Morton C.O., White L.P. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst Rev. 2019;9(9):CD009551. doi: 10.1002/14651858.CD009551.pub4.
19.Boch T, Reinwald M, Spiess B, et al. Detection of invasive pulmonary aspergillosis in critically ill patients by combined use of conventional culture, galactomannan, 1–3-beta-D-glucan and Aspergillus specific nested polymerase chain reaction in a prospective pilot study. J Crit Care. 2018; 47:198–203.
20.Eigl S, Prattes J, Lackner M, et al. Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients. Crit Care. 2015;19(1):178.
21.Lahmer T, Rasch S, Schnappauf C, Beitz A, Schmid RM, Huber W. Comparison of serum galactomannan and 1,3-beta-D-glucan determination for early detection of invasive pulmonary aspergillosis in critically ill patients with hematological malignancies and septic shock. Mycopathologia. 2016;181(7-8):505-511. doi:10.1007/s11046-016-0011-x.
22.Imbert S, Gauthier L, Joly I, Brossas JY, Uzunov M, Touafek F, Brun S, Mazier D, Datry A, Gay F, Fekkar A. Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients. Clin Microbiol Infect. 2016;22(6): 562.e1-8. doi: 10.1016/j.cmi.2016.01.027.
23.Sehgal IS, Dhooria S, Choudhary H, Aggarwal AN, Garg M, Chakrabarti A, et al. Utility of serum and bronchoalveolar lavage fluid galactomannan in diagnosis of chronic pulmonary aspergillosis. J Clin Microbiol. 2019;57(3): e01821-18. doi:10.1128/JCM.01821-18.
24.Kono Y, Tsushima K, Yamaguchi K, Kurita N, Soeda S, Fujiwara A, Sugiyama S, Togashi Y, Kasagi S, To M, To Y, Setoguchi Y. The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis.Respir Med. 2013;107(7):1094-100. doi: 10.1016/j.rmed.2013.04.007.
25.Park SY, Lee SO, Choi SH, Jeong JY, Sung H, Kim MN, Choi CM, Hong SB, Oh YM, Shim TS, Lim CM, Koh Y, Kim DS, Kim YS, Woo JH, Kim SH. Serum and bronchoalveolar lavage fluid galactomannan assays in patients with pulmonary aspergilloma. Clin Infect Dis. 2011;52(7):149-52. doi: 10.1093/cid/cir027.
26.Kitasato Y, Tao Y, Hoshino T, Tachibana K, Inoshima N, Yoshida M, Takata S, Okabayashi K, Kawasaki M, Iwanaga T, Aizawa H. Comparison of Aspergillus galactomannan antigen testing with a new cut-off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology.2009;14(5):701-8. doi: 10.1111/j.1440-1843.2009.01548. x.
27.Fujiuchi S, Yamamoto Y, Takeda A, Nishigaki Y, Fujit Y, Yamazaki Y, Fujikane T, Osanai S, Ohsaki Y. [Evaluation of galactomannan antigen and beta-D-glucan value for diagnosis of chronic necrotizing pulmonary aspergillosis]. Nihon Kokyuki Gakkai Zasshi. 2009;47(1):7-11.
28.Sehgal IS, Dhooria S, Choudhary H, Aggarwal AN, Garg M, Chakrabarti A, et al. Utility of serum and bronchoalveolar lavage fluid galactomannan in diagnosis of chronic pulmonary aspergillosis. J Clin Microbiol. 2019;57(3):e01821-18. doi:10.1128/JCM.01821-18.
29.Shin B, Koh WJ, Jeong BH, Yoo H, Park HY, Suh GY, Kwon OJ, Jeon K. Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis. J Infect.2014;68(5):494-9. doi: 10.1016/j.jinf.2014.01.005.